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Abstract
Object: Malignant gliomas are incurable, primary brain neoplasms noted for their potential to extensively invade brain
parenchyma. Current methods of clinical imaging do not elucidate the full extent of brain invasion, making it difficult to
predict which, if any, patients are likely to benefit from gross total resection. Our goal was to apply a mathematical
modeling approach to estimate the overall tumor invasiveness on a patient-by-patient basis and determine whether gross
total resection would improve survival in patients with relatively less invasive gliomas.
Methods: In 243 patients presenting with contrast-enhancing gliomas, estimates of the relative invasiveness of each
patient’s tumor, in terms of the ratio of net proliferation rate of the glioma cells to their net dispersal rate, were derived by
applying a patient-specific mathematical model to routine pretreatment MR imaging. The effect of varying degrees of
extent of resection on overall survival was assessed for cohorts of patients grouped by tumor invasiveness.
Results: We demonstrate that patients with more diffuse tumors showed no survival benefit (P = 0.532) from gross total
resection over subtotal/biopsy, while those with nodular (less diffuse) tumors showed a significant benefit (P = 0.00142) with
a striking median survival benefit of over eight months compared to sub-totally resected tumors in the same cohort (an 80%
improvement in survival time for GTR only seen for nodular tumors).
Conclusions: These results suggest that our patient-specific, model-based estimates of tumor invasiveness have clinical
utility in surgical decision making. Quantification of relative invasiveness assessed from routinely obtained pre-operative
imaging provides a practical predictor of the benefit of gross total resection.
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Introduction
High grade gliomas are diffusely invasive primary brain tumors
known for their resistance to therapeutic intervention. The benefit
of extensive resection of invasive gliomas has long been debated
(c.f, [1–4]) and the diffuse nature of the disease precludes a surgical
cure, as even hemispherectomies are followed by tumor recurrence
[5,6]. Several studies have identified factors correlated with post-
operative survival, such as tumor location and volume, measures
of the patient’s clinical status such as the Karnofsky Performance
Score (KPS), and patient age [1,7–9]. Given the significant
heterogeneity in tumor growth and response to treatment among
individual patients, a large patient sample is essential when
assessing the variable benefit of cytoreductive surgery. Although
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there is some conflicting data in the literature, recent population
level studies of at least 400 patients each have shown evidence for
incremental survival benefits with a larger extent of resection
(EOR) [1,2,4,10]. The comprehensive nature and large scope of
these retrospective studies provides insight into the differential
benefits of resection at a population level. Here we expand on this
work by retrospectively quantifying the degree of diffuse invasion
across patients and determining whether this metric can discrim-
inate those patients that benefited more from extensive surgical
resection. We hypothesized that the patients with the less invasive
tumor proliferation will demonstrate a relatively larger benefit
from gross total resection (GTR).
Recent studies supporting the clinical importance of resection
have been accompanied by technological advances that improve
neurosurgeons’ ability to safely remove the maximum amount of
tumor. Intraoperative MRI guidance, 11C-methionine PET
imaging, and 5-aminolevulinic acid-induced fluorescence are
among the tools currently used to optimize glioma resection
[11–14]. Determining the survival benefit that results from
increasing the EOR on a case-by-case basis could help direct the
use of these advanced surgical adjuncts toward those patients who
stand to gain the most from their application and, importantly,
identify patients that are unlikely to benefit.
Glioma patients are routinely evaluated with MR imaging
which only captures the ‘‘tip of the iceberg’’ of the tumor’s
diffusion profile. Specifically, gadolinium enhanced T1-weighted
(T1Gd) MR imaging outlines the leaky angiogenic neovasculature
associated with the highly cellular regions of glioma and T2-
weighted (T2) MRI reveals diffusely invaded glioma cells and
associated edema. Neither imaging technique can reveal the full
extent of the glioma invasion. Coincident with the evolving
literature on the potential benefits of extensive resection, we, and
other researchers at the interface of the quantitative and clinical
sciences, have been developing patient-specific biomathematical
modeling of glioma proliferation and invasion. Specifically, by
incorporating patient-specific mathematical modeling and data
from routine MR imaging, we have developed techniques for
determining the extent of diffuse invasion invisible on routine MRI
in individual patients [15–22]. Over the last decade, we have
applied these techniques extensively to quantify patient-specific
metrics of net proliferation rate (r) and net invasion rate (D) which
inform patient-specific simulations of glioma growth and progres-
sion within the human brain (c.f., Figure 1). Although these
simulated glioma cell density distributions are estimated by
simplifying assumptions regarding the role of T1Gd and T2
MRI in detecting different glioma cell densities, these methods
have been highly successful in generating clinically relevant
patient-specific metrics of tumor aggressiveness [19–21]. Postmor-
tem verification of model predictions demonstrate that cell density
simulations recapitulate the histologically-observed diffuse inva-
sion of glioma cells peripheral to the imaging abnormality [23],
Furthermore, the patient-specific model predictions are prognos-
tically significant [18,20]. The patient-specific metrics of net
proliferation rate, r, and net invasion rate D have been
quantitatively correlated to other measures of biological aggres-
siveness including hypoxic tumor burden assessed on [18F] fluoro-
misonidazole (FMISO) PET [21] allowing predictive simulation of
patient-specific FMISO-PET images strikingly similar to the actual
clinical observations [24]. In a study extending the modeling
approach to incorporate radiotherapy [20], the model has been
shown to predict patient-specific radiosensitivity using routine pre-
treatment clinical imaging information [22]. In a study of 70
patients treated with various extents of resection, our modeling
approach accurately predicted the population-level survival
difference between the biopsy/subtotal resection (Bx/STR)
populations and the gross-total resection population [19] but this
study was insufficiently powered to allow for cohorting patients
according to their relative invasiveness (r/D) to assess the benefit
of more extensive resection.
In the current study, we applied our novel mathematical
modeling approach to a cohort of 252 patients with contrast-
enhancing tumor on pre-treatment MRI. We studied the
relationship between patients’ relative tumor invasiveness and
the benefit of GTR, defined as complete removal of the
abnormality visible on T1Gd. To demonstrate the utility of our
approach in clinical decision-making, we included contrast-
enhancing gliomas of all grades (at presentation) to reflect the
perspective of the neurosurgeon, who must make surgical decisions
prior to histological assessment of tumor grade. Further, although
previous population-level studies of resection have set benchmarks
for the EOR (measured in terms of percent of the gadolinium-
enhanced T1-weighted, T1Gd, MRI abnormality removed)
needed to predict a positive post-operative prognosis, these scales
Figure 1. Patient-Specific Simulations of Tumor Cell Distribu-
tion and Density for both a Relatively Diffuse and a Relatively
Nodular Glioblastoma. T1Gd and T2 MRIs for two newly diagnosed
glioblastoma patients, one relatively diffuse with a low r/D (a,c) and
one more nodular with a high r/D (b,d). A simulation of the diffuse
glioma extent predicted by the patient-specific simulation for the
diffuse (low r/D) patient (e) and the more nodular (high r/D) patient (f)
is overlayed on the T1Gd MRI with red and blue indicating high and low
(but nonzero) glioma cell density, respectively. The effect of GTR is
shown as a black region with a white outline and highlights the
significant diffuse extent of glioma cells remaining post-GTR. In the
more nodular (high r/D) case, GTR removes 75% of the pre-treatment
glioma cells leaving 8.4e8 cells while in the diffusely invasive (low r/D)
case, GTR removes only 27% of the pre-treatment glioma cells leaving
4.2e9 cells, an order of magnitude higher than the nodular case. The
large number of tumor cells remaining after resection of a diffuse tumor
drives recurrence.
doi:10.1371/journal.pone.0099057.g001
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do not account for patient-specific tumor growth rates or
invasiveness [1,9].The relationship between the T2:T1Gd ratio
(to infer information regarding the relative invasiveness of the
disease) and survival has been investigated by others [8], but our
work advances this type of analysis by calculating a patient-specific
measure of the diffusion and proliferation rates, which we used to
estimate the number of glioma cells remaining after surgery. Our
hypothesis is that this transition from population-level studies of
surgical benefit to patient-specific analysis yields information that
can be used clinically to determine the benefit a particular patient
will receive from more extensive resection. To our knowledge, this
is the first application of patient-specific mathematical modeling in
neuro-oncology to study such a large (n.200) cohort of patients
leading to results that have significant implications for the routine
clinical management of contrast-enhancing gliomas.
Methods
Patients and Clinical Data
We consider a cohort of 252 contrast-enhancing glioma patients
at first diagnosis in our observational study, approved by the
University of Washington institutional review board. Written
consent was obtained and securely stored for the duration of the
study per the principles of the Declaration of Helsinki. Pathological
grade information at diagnosis was available for 247 patients out of
the 252 (220 grade IV, 21 grade III, six grade II and five patients of
unknown grade). Of the 252 patients, 211 were diagnosed, treated
or consented at the University of WashingtonMedical Center, 35 at
Columbia University, and six at University of California at Los
Angeles Medical Center. Nine patients were excluded due to
unconfirmed extent of resection, due to lack of post-operative
imaging and imaging report. All of these patients had a pre-
treatment T1Gd and T2/FLAIR image from the same time point.
Extent of resection was classified as GTR, STR or Bx based on post-
operative radiology report (N=243). In addition, we quantified the
extent of resection as the percent of T1Gd resected using pre- and
post-operative imaging, when available (N=181).
Model Parameter Calculation
Our analysis employs a mathematical model that equates rate of
change of glioma cell concentration to net invasion and net
Figure 2. r/D Assessment. This figure presents an overview of how the ‘‘relative invasiveness,’’ or r/D, is obtained. Tumor volumes are segmented
from T1Gd and T2 MRI. The measured volume is approximated with a sphere in order to obtain a radius. The T1Gd and T2 radii are associated with
different levels of detection, with T2 at low tumor cell density and T1Gd abnormality associated with high tumor cell density. The relationship
between these two radii describes the steepness of the tumor cell profile, or ‘‘relative invasiveness.’’
doi:10.1371/journal.pone.0099057.g002
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c = tumor or cell density at location x and time t
D= the dispersal of tumor cells
r=net proliferation rate of tumor cells
k = cell carrying capacity
x = location in the brain
This model portrays the leading edge of the glioma as an
advancing traveling wave. The shape and the speed of this
wavefront are individualized to each patient by estimating the net
rates of diffusion (D) and proliferation (r) prior to treatment byy
associating the T1Gd and T2 enhancing regions as corresponding
to different levels of cell density on this wave. Given sizes on T1Gd
and T2 MRI one can calculate a measure of invasiveness, r/D,
which is related to the ‘gradient’ between these two assumed cell
density levels (Figure 2). This relationship is known to be highly
non-linear and provides a unique individual profile of diffuse
invasion at the leading edge of the imageable tumor [23] [15–
17,20,27,28], [15–17,20–22,27] which can be used to generate
patient-specific invasion profiles from pre-treatment MRIs (high
r/D: Figure 1a,c,e. low r/D: Figure 1b,d,f). The most diffuse
tumors (low r/D) are those with a low proliferative potential (r)
relative to their invasive potential (D); the least diffuse, most
nodular, tumors (high r/D) are those with a high proliferative
potential relative to their invasive potential. We estimated tumor
volumes from T1Gd and T2/FLAIR MRIs using a semi-
automated image segmentation method we developed previously
in Matlab [22]. The time between images used for analyzing
resection and tissue diagnosis was minimized in order to capture
tumor dynamics just prior to therapeutic intervention. The mean
time difference was 1.7 days, and the median was 4.5 days (0–112
day range). Using the pre-treatment MRIs and the invasiveness
metric, we can simulate the tumor cell density over space even
peripheral to the abnormality seen on imaging (heat map in
Figure 1), and estimate the resection margin needed to remove
99% of the glioma (green contours in Figure 3b and 3c).
Specifically, by computationally masking out the region of the
T1Gd abnormality to approximate a gross total resection
(Figures 1e and 1f), we are able to visualize and quantify the
predicted extent of glioma cell distribution following removing
varying extents of resection – [29]. This reveals a drastically
different pattern of residual disease for the more diffuse glioma
(low r/D – Fig. 1e) when compared to the more nodular glioma
(high r/D – Figure 1f). Using measurements of the tumor volume
resected, number of residual cells left was estimated for patients
with post-operative imaging. Within each invasiveness cohort,
each possible cutoff for number of cells remaining was used to
separate patients into groups with relatively large and small
estimated numbers of residual tumor cells. Log rank tests assessed
the difference between survival curves for these groups within each
cohort, for each cutoff.
Statistical Analysis
We used the PASW Statistics 18 software package to obtain
descriptive statistics. The Kaplan-Meier survival analysis (log-rank
test) was performed in Matlab. For all statistical tests we
considered P-values less than or equal to 0.05 to be significant.
Results
We performed a survival analysis to compare GTR to STR/Bx
in the overall patient cohort, as confirmed by post-operative
imaging, revealing an improvement in overall survival approach-
Figure 3. Extent of resection necessary to attain significant reduction in glioma cell burden. A) Simulated predictions of the additional
resection volume beyond GTR of the T1Gd abnormality needed to achieve 99% reduction in tumor cell burden, a 2 log kill of tumor cells. The color
scale maps to the additional volume (ranging from 1021.5 to 102.8, corresponding to hemispherectomy of an approximately 1200 cm3 brain volume)
outside of the T1Gd abnormality needed to attain desired tumor cell removal. The cutoffs between low and moderate r/D (37.2 cm22) and moderate
and high r/D (135 cm22) are displayed as tick marks on the horizontal axis. These theoretical resection margins necessary to achieve a 2 log kill of
tumor cells are visualized for b) a diffuse tumor which requires an extra 237 cc of tissue (green contour) to be removed beyond a conventional GTR of
the T1Gd abnormality (pink contour). In contrast, only 25 cc of brain tissue needs to be resected to remove 99% of the glioma cells in the more
nodular glioma (c).
doi:10.1371/journal.pone.0099057.g003
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ing statistical significance amongst those receiving GTR (p= 0.08).
To test the hypothesis that a subset of patients drive the observed
survival benefit of GTR, patients were cohorted according to
relative invasiveness. All 243 contrast-enhancing glioma patients
were equally divided into three cohorts according to the relative
level of invasiveness of their disease: ‘‘diffuse’’ with a low
proliferative to invasive ratio (low r/D, 0.07–0.38 mm22),
moderately invasive with a moderate proliferative to invasive ratio
(mid r/D, 0.38–1.30 mm22) and ‘‘nodular’’ with a high
proliferative to the invasive ratio (high r/D,1.30–294.1 mm22).
Dividing the population in this way provides cohorts with sufficient
N to allow for survival analysis across scales of relative invasiveness
whereas progression-free survival data, available in 102 patients
but failed to reach significance in either the overall or sub cohorts.
Age, KPS, grade and treatment data are summarized in
Table 1. There was no statistical difference in age across
invasiveness cohorts (P = 0.93, ANOVA test). There was no
difference in KPS between invasiveness cohorts (P = 0.25,
ANOVA test). The mean KPS scores at diagnosis in the GTR
and Bx/STR groups were 83.7 and 78.1 respectively, showing a
Table 2. Cox Proportion-Hazards Regression for Survival Data.











0.18 0.0000** 0.27 0.0000**
Age 0.01, 0.0001, 0.03, 0.0001,
KPS 0.79 0.0001** 0.83 0.0005**
XRT Dose 0.05 0.0000** 0.15 0.0000**
Concurrent TMZ 0.31 0.78* 0.18 0.99*
r/D 0.19 0.04** 0.26 0.12*
Grade 0.9 0.0004** N/A N/A
Race 0.55 0.15* 0.31 0.26*
EORCriteria 0.14 0.0000** 0.17 0.0000**
Gender 0.83 0.83* 0.97 0.84*
Dx In 90s 0.95 0.35* 0.93 0.42*
Dx In 2000s 0.55 0.03** 0.45 0.03**
Pre-op Steroid 0.69 0.12* 0.92 0.11*
T1Gd 0.12 0.81* 0.26 0.83*
T2 0.23 0.48* 0.26 0.35*









Age 0.002, 0.0000, 0.0008, 0.0000,
KPS 0.0007, 0.0000, 0.005, 0.0000,
XRT Dose 0.04, 0.01, 0.59 0.0009**
Concurrent TMZ 0.02, 0.002, 0.15 0.0000**
r/D 0.17 0.86* 0.29 0.94*
Grade 0.39 0.0000** N/A N/A
Race 0.02, 0.03, 0.008, 0.18,
EORCriteria 0.0003, 0.009, 0.0007, 0.0002,
Gender 0.59 0.95* 0.4 0.54*
Dx In 90s 0.39 0.0000** 0.22 0.0001**
Dx In 2000s 0.51 0.0000** 0.32 0.0002**
Pre-op Steroid 0.06 0.44* 0.11 0.45*
T1Gd 0.52 0 0.44 0.02**
T2 0.32 0.01* 0.61 0.02**
Cox Proportion-Hazards Regression Analysis for Survival Data, multivariate (A) and univariate (B) analysis.
* indicates that Cox proportional hazard (Coxph) assumptions were met, and that the given variable does not have a significant effect on survival at the P = 0.05
significance level.
** indicates that Coxph assumptions were met, and that the given variable does have a significant effect on survival at the P = 0.05 level. As expected, variables such as
age and KPS have a significant effect on survival.
,indicates variables for which the Coxph assumption was not met.
doi:10.1371/journal.pone.0099057.t002
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slight reflection of the bias toward higher KPS expected in patients
who are candidates for GTR. There was no statistical difference in
proportion of patients receiving GTR versus Bx/STR between
cohorts (P = 0.39, Proportion chi-square test).There was no
statistical difference in radiation dose received across cohorts
(P = 0.22, ANOVA). Post-operative complications were rare with 1
confirmed in each invasiveness cohort with two cranial infections
and one fever of unknown origin (presumed toxic encephalopa-
thy). The median radiation dose in all three groups was 6000 cGy,
with means of 5827 cGy, 5624 cGy, and 6004 cGy for the diffuse,
moderate, and nodular groups respectively. There was no
statistical difference in proportion of patients who received
concurrent Temozolomide with radiation or steroid use between
patients who had a GTR versus patients who had less extensive
resections (P = 0.73 and P=0.62 respectively, Proportion chi-
square test).
Table 2 shows the multivariate and univariate Cox proportion-
hazards regression analysis. Additional Cox proportion-hazards
regression analysis performed for each invasiveness cohort is
detailed in Table S1. Age, KPS, XRT dose, concurrent
Temozolomide, tumor grade, race, EOR, decade of diagnosis,
and T1Gd lesion size have a significant effect on survival at the
P= 0.05 level of significance. Even given the challenge of
multivariate analysis on a relatively modest patient cohort, relative
invasiveness (r/D) was significant in the overall patient population
and neared significance in the nodular cohort.
Analysis of the pre-operative images of all contrasting-enhanc-
ing gliomas at initial diagnosis revealed that patients with diffuse
and moderate did not receive a significant survival benefit from
GTR compared to Bx/STR (p= 0.53, p = 0.45, respectively,
Figure 4a–b). In contrast, patients with the least invasive and most
nodular of the contrast enhancing gliomas (high r/D) survived
significantly longer if they received GTR versus Bx/STR
(p= 0.001, Figure 4c). This median difference represents a survival
advantage of 227 days, a 7.5 month or 65% improvement over the
Bx/STR cohort. To be consistent with recent publications
suggesting a threshold of removal of 78% of the T1Gd
abnormality as being necessary to achieve significant overall
Figure 4. Survival Curves for Highly Diffuse (low r/D), Moderately Diffuse (mid r/D), and Nodular (high r/D) for 243 Contrast-
enhancing Gliomas. Comparisons were made between biopsy/subtotal resection (BX/STR) and gross total resection (GTR) in all 243 contrast-
enhancing gliomas. A–B) Comparing Bx/STR with GTR in 243 contrast enhancing gliomas at first surgical presentation, there is no significant survival
benefit of GTR for highly and moderately diffuse (low and mid r/D, p = 0.532, p = 0.445, respectively). C) Patients with the least diffuse and most
nodular pattern of growth (high r/D) that underwent GTR had a significant survival benefit over patients undergoing Bx or STR (p = 0.00142). Median
increase in survival was 227 days (7.5 months) or a 65% improvement over the BX/STR population. When EOR was classified by percent of the T1Gd
volume removed, with 76% selected as the cut off, the same selective survival benefit is observed in the nodular cohort (D–F, p = 0.00132). The limits
between highly and moderately diffuse, and between moderately diffuse and nodular r/D were 0.376 mm22 and 1.30 mm22, respectively.
doi:10.1371/journal.pone.0099057.g004
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survival benefit in a cohort of patients [2], we assessed quantitative
measures of EOR based on volumetric quantification pre and
post-resection in a subset of our cohort for which such imaging was
available (N= 181). Resection was quantified for the subset of
patients with sufficient imaging, and resection was categorized as
more or less extensive based on a 78% cutoff. This quantification
of tumor volume resected displays the same selective survival
benefit in the nodular cohort (diffuse: p = 0.94, moderate: p = 0.93,
nodular: p = 0.001, Figure 4d–f).
Since we restricted our initial analysis to all CE tumors to reflect
the reality that the surgeon does not know the grade prior to
completing surgery, we wanted to confirm that our results were
not skewed by a small number of low-grade gliomas within the
population. By limiting the analysis to only the WHO grade IV
GBMs (N= 220), we found that, again, GTR imparts no
significant survival advantage in patients with more invasive
GBMs (Figure 5a, b). In contrast, GTR does impart a significant
survival advantage among patients with the least invasive nodular
GBMs (p= 0.0003, Figure 5c), providing a median increase in
survival time of 239 days (8 months). This 8 month median
survival benefit is equivalent to an 80% improvement in median
survival time for these patients over the Bx/STR cohort. Similar
to the BX/STR vs GTR comparison, we found that only the
nodular cohort of GBM patients displayed a significant survival
benefit from resection of greater than or equal to 78% of the
T1Gd abnormality (p = 0.00003, Figure 5d–f).
Our computational analysis allows us to quantitatively estimate
the amount of tumor remaining post-resection including areas
peripheral to the imaging abnormality – cf., Figure 1. We are able
to generate simulated resections informed by the estimates of
cellular density simply with measurements of r/D and radius of
the visible tumor on T1Gd MRI. Fully acknowledging that
surgical planning is a complex clinical process and that each
patient may not be a candidate for the extent of resection the
model predicts, Figure 3a represents the increase in volume of
resection needed over what would be considered a GTR on
imaging alone to leave 1% of glioma cells remaining (2 log cell kill)
after such an extensive resection, featuring 2 illustrative patients in
Figures 3b and 3c. GTR of the T1Gd area in nodular (high r/D)
lesions removes nearly 99% of the tumor cells, but the additional
Figure 5. Survival Curves for Highly Diffuse (low r/D), Moderately Diffuse (mid r/D), and Nodular (high r/D) for 215 WHO Grade IV
glioblastoma multiforme tumors (GBMs) with sufficient imaging. Comparisons were made between biopsy/subtotal resection (BX/STR) and
gross total resection (GTR) in GBMs at first surgical presentation. GTR imparted no significant survival benefit in the highly diffuse (A) and moderately
diffuse (B) GBMs. C) GTR imparted a significant survival benefit among patients with nodular GBMs, with a benefit of 239 days (8 months), or a 75%
improvement over the Bx/STR group. When EOR was classified by percent of the T1Gd volume removed, with 76% selected as the cut off, the same
selective survival benefit is observed in the nodular cohort (D–F, p = 0.0000339). The limits between highly diffuse and moderately diffuse, and
between moderately diffuse and nodular r/D were 0.439 mm22 and 1.36 mm22, respectively.
doi:10.1371/journal.pone.0099057.g005
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resection volume would need to be extended significantly for
patients with diffuse (low r/D) gliomas (Figure 3a). Figure 3b
illustrates this point for a representative patient with diffuse disease
(low r/D). That is, to achieve a cytoreductive effect of resection to
remove 99% of the tumor cells diffusely extended in the brain
would require a highly unrealistic 237cc of additional tissue to be
removed peripheral to the imaging abnormality seen on T1Gd. In
contrast, only 25cc of additional tissue would have to be removed
in order to achieve the same 99% reduction in the patient with
high r/D shown in Figure 4c. These illustrative patient cases and
the relationship quantified in Figure 3a shows that the most diffuse
gliomas require a dramatically increased tumor margin whereas
the most nodular gliomas require only a modest increase to attain
a minimal residual of 1% of the total glioma cells in the brain.
Combining the model with patient-specific measures of relative
invasion, r/D, the calculated extent of resection were used to
estimate the number of cells remaining post-resection for each
patient (N= 181). To determine if there is a threshold of glioma
cells remaining following resection that portends better outcomes,
iterative Kaplan-Meier analysis was performed using each possible
threshold to separate invasiveness cohorts into groups with
relatively small and large residual cell populations (Figure 6).
The moderate and nodular cohorts (mid and high r/D,
respectively) show robust thresholds for identifying patients with
longer survival (white bins with black asterisks).
Discussion
Our results show that for patients with less diffuse, nodular
tumors (high r/D), GTR imparts a significant survival benefit;
whereas GTR does not afford any significant survival benefit in
patients with more diffuse tumors. Though other studies have seen
a modest population-scale survival benefit with increasingly
extensive resections of the T1Gd abnormality [1,2], our results
suggest that the difference seen in the survival curves when
considering the entire population of GBMs may have been driven
by the subset of GBM patients with less diffuse disease. Therefore,
the model-based estimate of tumor invasiveness that we used for
our analysis (r/D) could potentially act as a metric for identifying
glioma patients that are more likely to benefit from GTR.
Although the approach described here relies on detailed,
quantitative, computational representations of the pre-operative
tumor, our method basically synthesizes and quantifies the
neurosurgical intuition as to which patients will most likely benefit
from GTR. In addition to basic patient data such as age and KPS
and symptomatic considerations such as intracranial pressure
reduction, the individual tumor growth characteristics applied
here can also inform the physician’s perspective on each patient’s
illness. Understanding the behavior of the disease is necessary for
understanding how the tumor will respond to treatment. This
motivates a future prospective validation study in which the
optimal r/D cut-off and simulations of tumor growth after varying
extents of resection will improve our ability to determine the likely
benefit gained from surgical intervention.
Further study is needed to understand the degree to which gross
total resection or more extensive resection should be advocated in
patients for which functional deficits are likely to result from
surgery, as previous studies have shown that such deficits poorly
impact survival [30]. Although recent studies have suggested that
more aggressive resections are most beneficial, these GTRs also
carry a higher risk of immediate post-operative deterioration [31].
Understanding the extent of cytoreduction achieved by aggressive
surgery for each patient will help surgeons evaluate the potential
benefit in taking the known risk associated with this treatment.
As technological innovations continue to propel surgeons’
ability to achieve greater EOR, it will become increasingly
important to identify the subset of glioma patients who will truly
benefit from gross total resection [7]. Since the degree of benefit
appears to be so profound in patients with high r/D (75—80%
improvement over the STR/Biopsy cohort), these results suggest
that a subtle selection bias towards these relatively less invasive
gliomas in any uncontrolled or small study could lead to over
Figure 6. Results of iterative Kaplan-Meier Analysis in each invasiveness cohort. Number of cells remaining was calculated for each
patient, based on their r/D and measured residual enhancing disease. Each possible threshold was iterated through to separate the patients into
large and small residual tumor cell population cohorts. White boxes correspond to thresholds separating patients into groups with significantly
different (p,0.05) survival. White stars indicate tests with no p-value, as the threshold did not separate the patients in the given invasiveness cohort
into two groups. Black asterisks indicate tests with p,0.05. Black bins with white x’s indicate no the threshold did not separate the patients in the
given invasiveness cohort into two groups. For example, for the diffuse case (Figure 3, top row), the black bins with white x’s represent the fact that
even GTR was unable to achieve a remaining cell burden less than the cutoff (up to approximately 109). Further, amongst the most diffuse gliomas,
no threshold for a residual cells following resection was found to be significant of outcome represented visually as the lack of a white bar in the top
row. Although less dramatic, the moderate cohort was unable to equate a GTR with ,108.5 cells remaining represented by the black bars with white
x’s to the left on middle row of Figure 3. While resection of tumors in the nodular cohort were able to attain residual disease burdens at all levels
down to ,107 cells.
doi:10.1371/journal.pone.0099057.g006
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estimation of robust median survivals with no true clinical benefit.
Incorporation of work by the RANO group to better define and
consider postoperative changes on MRI could further improve
EOR classification [32]. Given the advent of intraoperative
imaging as a means of confirming resection of imageable disease,
these methods could develop as an adjunct to such approaches
that incorporate knowledge of the diffuse extent of tumor invasion
peripheral to the imaging abnormality. Our results suggest that a
prescribed subset of patients may benefit from surgical resection
that extends beyond the margins defined by T1Gd MRI. We
envision that a new neurosurgical planning tool that combines our
modeling approach with functional mapping could better define
the surgical margins that maximize cytoreduction while preserving
neurological function. This could be combined with recent tools
we have developed to use patient-specific simulations of tumor
growth to generate metrics of treatment response found that are
prognostically significant [28,33] to begin a patient-centered suite
of tools for treatment decision support.
This study also suggests future analyses to determine if there are
other biological features of less diffuse (high r/D) patients that
make them more responsive to GTR. We have previously shown
that these nodular tumors are more likely to be hypoxic [21] and
may have worse prognosis overall [20] but paradoxically receive a
larger benefit from aggressive treatment [18]. This may be due to
a combination of factors, such as the observation that nodular
(high r/D) patients tend to have larger net proliferation rates (r)
and thus the time course to significant tumor recurrence is
decreased for such aggressive tumors.
Conclusions
Using pre-operative MRI to quantify the invasion profile,
patients with low relative invasiveness are most likely to benefit
from GTR with a striking 80% improvement in survival over their
STR/Bx controls. This provides a practical therapeutic strategy
for neurosurgeons in the context of invasive gliomas, and a method
for cohorting patients in clinical trial design to identifying the
cohort of patients benefiting strongly from GTR. By character-
izing the disease itself in a patient-specific manner, we are able to
inform a long-standing debate as to the role of resection in the
treatment of diffuse gliomas.
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